Reveglucosidase alfa

Drug Profile

Reveglucosidase alfa

Alternative Names: BMN-701; GILT-rhGAA - BioMarin Pharmaceutical; GILT-tagged recombinant human GAA; IGF2-GAA; ZC-701

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ZyStor Therapeutics
  • Developer BioMarin Pharmaceutical
  • Class Alpha-glucosidases; Recombinant fusion proteins
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glycogen storage disease type II

Most Recent Events

  • 30 Jun 2016 Discontinued - Phase-I/II for Glycogen storage disease type II in France (IV)
  • 30 Jun 2016 Discontinued - Phase-II for Glycogen storage disease type II in Australia (IV)
  • 30 Jun 2016 Discontinued - Phase-III for Glycogen storage disease type II in Portugal, Germany, Italy, Italy, Belgium, United Kingdom, USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top